Acurx Pharmaceuticals Files 8-K
Ticker: ACXP · Form: 8-K · Filed: Sep 22, 2025 · CIK: 1736243
Sentiment: neutral
Topics: corporate-update, filing
Related Tickers: ACRX
TL;DR
ACRX filed an 8-K on 9/22/25 for corporate updates and financials.
AI Summary
Acurx Pharmaceuticals, Inc. filed an 8-K on September 22, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, incorporated in Delaware, has its principal executive offices at 259 Liberty Avenue, Staten Island, NY 10305.
Why It Matters
This filing indicates corporate updates and financial reporting for Acurx Pharmaceuticals, Inc., which could impact investors' understanding of the company's structure and financial status.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain significant new risks.
Key Players & Entities
- Acurx Pharmaceuticals, Inc. (company) — Registrant
- September 22, 2025 (date) — Date of earliest event reported
- 259 Liberty Avenue, Staten Island, NY 10305 (address) — Principal executive offices
- 001-40536 (filing_id) — Commission File Number
FAQ
What specific amendments were made to Acurx Pharmaceuticals, Inc.'s articles of incorporation or bylaws?
The filing indicates amendments were made, but the specific details of these amendments are not provided in the summary text.
What is the primary business of Acurx Pharmaceuticals, Inc.?
Acurx Pharmaceuticals, Inc. is in the business of Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code [2834].
When was Acurx Pharmaceuticals, Inc. incorporated?
Acurx Pharmaceuticals, Inc. was incorporated in Delaware.
What is the IRS Employer Identification Number for Acurx Pharmaceuticals, Inc.?
The IRS Employer Identification Number is listed as 82-3733567.
What is the fiscal year end for Acurx Pharmaceuticals, Inc.?
The fiscal year end for Acurx Pharmaceuticals, Inc. is December 31 (1231).
Filing Stats: 538 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2025-09-22 16:42:31
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ACXP The Nasdaq Stock Mar
Filing Documents
- tm2526666d1_8k.htm (8-K) — 26KB
- tm2526666d1_ex3-1.htm (EX-3.1) — 8KB
- 0001104659-25-092166.txt ( ) — 200KB
- acxp-20250922.xsd (EX-101.SCH) — 3KB
- acxp-20250922_lab.xml (EX-101.LAB) — 33KB
- acxp-20250922_pre.xml (EX-101.PRE) — 22KB
- tm2526666d1_8k_htm.xml (XML) — 4KB
03 Amendments to Articles of Incorporation
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. At the special meeting of stockholders of Acurx Pharmaceuticals, Inc. (the "Company") held on September 16, 2025, the Company's stockholders approved an amendment (the "Amendment") to the Company's Certificate of Incorporation, as amended, to increase the total number of authorized shares of the Company's common stock from 200,000,000 to 250,000,000. On September 22, 2025, the Company filed the Amendment with the Secretary of State of the State of Delaware with immediate effect. The summary of the Amendment contained herein does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is attached as Exhibit 3.1 hereto and incorporated herein by reference.
01 Financial Statements
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibits are filed with this Current Report on Form 8-K: Exhibit No. Description 3.1 Certificate of Amendment to the Certificate of Incorporation, as amended, dated September 19, 2025 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized. Acurx Pharmaceuticals, Inc. Date: September 22, 2025 By: /s/ David P. Luci Name: David P. Luci Title: President and Chief Executive Officer